Marrow Therapeutics raises $120m Series B for bone marrow-targeted medicines
OrbiMed led the round as Marrow advances its lead program for sickle cell disease and beta thalassemia.
Marrow Therapeutics announced a $120 million Series B led by OrbiMed on 17 November 2026. Returning Series A investors and new institutional backers participated. The company separately disclosed its earlier $53 million Series A, bringing combined financing to $173 million. Marrow is advancing MAR-101 through studies preparing for clinical development in sickle cell disease and beta thalassemia.
Use of funds
Develop bone marrow-targeted genetic medicines
Advance MAR-101 toward clinical development